Company news
Bluenergies Ltd. news in 2018
Bluenergies Ltd.'s news releases, calls and decks from 2018, newest first.
BELLUS Health Updates BLU-5937 Top-Line Phase 1 Results Timeline to November 2018
November 14, 2018
BELLUS Health Announces Issuance of New U.S. Patent Claiming P2X3 Selectivity as a Means of Minimizing Taste Effects for its Lead Chronic Cough Drug Candidate BLU-5937
October 31, 2018
BELLUS Health Announces Appointment of Clinical Advisory Board
September 25, 2018
BELLUS Health to Present at Baird 2018 Global Healthcare Conference
August 30, 2018
BELLUS Health Reports Financial and Operating Results for the Second Quarter Ended June 30, 2018
August 8, 2018
BELLUS Health Announces Patent Protection Secured in All Major Pharmaceutical Markets for Lead Drug Candidate BLU-5937
July 19, 2018
BELLUS Health Initiates Phase 1 Clinical Study for its Chronic Cough Drug Candidate, BLU-5937
July 9, 2018
BELLUS Health Presents BLU-5937 Preclinical Data and Updated Phase 1 Timeline at 2018 International Cough Symposium
June 27, 2018
BELLUS Health to Present at the 2018 International Cough Symposium
June 20, 2018
BELLUS Health Reports Financial and Operating Results for the First Quarter Ended March 31, 2018
May 15, 2018
BELLUS Health Responds to Recent Share Price Appreciation and Increased Trading Activity
April 30, 2018
BELLUS Health to Present at Bloom Burton & Co. Healthcare Investor Conference
April 26, 2018
BELLUS Health Reports Financial and Operating Results for the Year Ended December 31, 2017
February 21, 2018
BELLUS Health Receives Milestone Payment from Taro Pharmaceuticals
January 9, 2018
BELLUS Health to Present at Biotech Showcase(TM) 2018 Conference
January 4, 2018